Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotech company using fMRI & AI for targeted biomarkers, accelerating neuropsychiatric drug development for pharma partners.
Ceretype Neuromedicine is a Cambridge, Massachusetts-based biotechnology company that integrates functional MRI with artificial intelligence to develop targeted biomarkers for neuropsychiatric drug development and patient care. The venture-backed startup provides a scalable technological platform that analyzes complex brain circuitry and subtypes brains neurobiologically to assist pharmaceutical partners in evaluating treatment impacts on neural networks. To support its ongoing commercial operations and research initiatives, the enterprise recently closed an oversubscribed $2 million second seed funding round led by Cedar Street Group. Additional financial backing for the clinical-stage organization comes from specialized healthcare investors including Leafy Tunnel and The One Mind Accelerator. The firm also maintains strategic industry partnerships with organizations such as Calyx to facilitate clinical trial imaging and accelerate therapeutic research across the neurology sector. Ceretype Neuromedicine was officially founded in 2020 by co-founders Emily Stern and David Silbersweig.
Ceretype Neuromedicine has raised $2.0M across 1 funding round.
Ceretype Neuromedicine has raised $2.0M in total across 1 funding round.
Ceretype Neuromedicine has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2024 | $2M Seed | Paul Francis | Leafy Tunnel, The ONE Mind Accelerator | Announced |
Ceretype Neuromedicine has raised $2.0M in total across 1 funding round.
Ceretype Neuromedicine's investors include Paul Francis, Leafy Tunnel, The One Mind Accelerator.